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PURPOSE. Neovascularization is a major cause of blindness in various ocular diseases. Bioactive
sphingosine 1-phosphate (S1P), synthesized by two sphingosine kinases (Sphk1, Sphk2),
emerged as a key player in a multitude of cellular processes, including cell survival,
proliferation, inflammation, migration, and angiogenesis. We investigated the role of Sphk2,
S1P, and S1P receptors (S1PR) during retinal neovascularization using the oxygen-induced
retinopathy mouse model (OIR).
METHODS. Sphk2 overexpressing (tgSphk2) and Sphk2 knockout (Sphk2/) mice were used
in the OIR model, exposed to 75% O2 over 5 days from postnatal day (P)7 to 12 to initiate
vessel regression. After returning to room air, these mice developed a marked neovascular-
ization. Retinae recovered from untreated and treated eyes at P7, P12, P14, and P17 were used
for lectin-stained retinal whole mounts, mass spectrometry, and quantitative real-time PCR.
RESULTS. tgSphk2 mice showed higher retinal S1P concentrations, accelerated retinal
angiogenesis, and increased neovascularization. Expression of S1PR, vascular endothelial
growth factor a (VEGFa), and angiopoietin 1 and 2 was differentially regulated during the
course of OIR in the different genotypes. Sphk2/ displayed a markedly reduced retinal
angiogenesis and neovascularization as well as decreased VEGFa and angiopoietin expression.
CONCLUSIONS. Using genetic models of Sphk2 overexpression or deletion we demonstrate a
strong impact of Sphk2/S1P on retinal vasculopathy and expression of vascular growth factors
like VEGF and angiopoietin in the retina. Consequently, Sphk2, S1P, and S1PR may offer
attractive novel therapeutic targets for ischemic retinopathies.
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Neovascularization is an integral process of impairment andloss of vision in ischemic retinopathies, a diverse group of
retinal diseases (e.g., diabetic retinopathy, retinopathy of
prematurity, and retinal vein occlusions). Retinal hypoxia caused
by retinal vessel occlusion or capillary nonperfusion in
retinopathies stimulates the production of angiogenic factors,
leading to intraocular neovascularization (NV).1–3 The predom-
inant growth factor associated with physiological and patho-
physiological angiogenesis is vascular endothelial growth factor
a (VEGFa). Several ocular cell types are known to express
VEGFa (e.g., Mu¨ller cells, pericytes, ganglion cells, and vascular
endothelial cells [ECs]), which plays a critical role in retinal
neovascularization.4 Besides VEGFa, other important angiogenic
factors are angiopoietin 1 (Angpt1) and angiopoietin 2 (Angpt2)
with their tyrosine kinase receptor Tie2, expressed on ECs.
Angpt1 binding to Tie2 stimulates receptor phosphorylation and
subsequently activates endothelial nitric oxide synthase (eNOS),
proteinkinase b (Akt), and extracellular-signal regulated kinase
(ERK). Angpt1/Tie2 signaling facilitates vessel stabilization and
maturation and maintains the integrity of blood vessels.4–8
Angpt2 acts as a Tie2 antagonist, competing with Angpt1, and
reduces receptor phosphorylation, leading to vessel destabiliza-
tion.9–11 Angpt2 expression increases in ischemic retina and
promotes neovascularization in cooperation with VEGFa. In the
absence of VEGFa, Angpt2 stimulates regression of neovascular-
ization and pruning of capillary beds.12,13
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Sphingosine 1-phosphate (S1P), a bioactive sphingolipid, is
an important signaling molecule involved in the regulation of
various cellular processes, such as cell survival, proliferation,
differentiation, angiogenesis, migration, and inflammation.14–18
In contrast, ceramides and sphingosine, two precursors of S1P,
are mediators of proapoptotic processes. Together with S1P,
these sphingolipid mediators maintain a balance, termed the
‘‘sphingolipid rheostat,’’ which is decisive for cell fate.19
Sphingosine kinases are central regulators of this equilibrium
and catalyze S1P production from sphingosine by phosphor-
ylation. There are two isoforms of sphingosine kinases (Sphk),
Sphk1 and Sphk2, which are ubiquitously expressed in all
tissues but differ in expression levels and subcellular localiza-
tion.20–22 Currently, Sphk1 is regarded as an enzyme involved
in prosurvival and proproliferative cascades while the func-
tions and regulations of Sphk2 are not as well characterized
and seem to be context dependent. Known Sphk2 functions
involve induction of growth arrest and apoptosis,23,24 but also
promotion of survival and proliferation.25 There is little
experimental evidence concerning the role of Sphk as possible
target of pharmacologic interventions in retinal diseases.
However, S1P is a key regulator of angiogenesis and vessel
stabilization26–28 and a decisive factor in retinal pathologies,19
contributing to retinal and choroidal neovascularization.29–32
S1P mainly exerts its biological effects via five membrane-
bound G protein–coupled receptors, S1PR1 to S1PR5.33 In
addition, Sphk2 inhibition was reported to reduce disease
severity in diabetic retinopathy.34
Here, we investigated the role of S1P and Sphk2 in retinal
vascular development and neovascularization using the oxy-
gen-induced retinopathy model (OIR) in mice. We found that
Sphk2 is the prominent Sphk isoform in the mouse retina.
Moreover, Sphk2 overexpressing mice (tgSphk2) and Sphk2
knockout mice (Sphk2/) were used to demonstrate that
Sphk2 has a major impact on retinal vascularization. Conse-
quently Sphk2 and its product S1P and S1P receptors may
prove promising novel targets for ischemic retinopathies.
MATERIALS AND METHODS
Animal Procedures
The protocols conformed to the German Protection of Animals
Act and the guidelines for care and use of laboratory animals by
the local committee (Regierungspraesidium Darmstadt) in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. Animals were housed with
free access to chow and water in a specified pathogen-free
facility with a 12-hour day/12-hour night cycle. Sphk2/ mice
with C57BL/6J background were generated and characterized
as previously described.22,35–37 Mice overexpressing the
human Sphk2 gene were generated by GenOway (Lyon Cedex,
France). Briefly, human Sphk2 transgene controlled by the
ubiquitous CAG promoter was introduced into the Hprt locus
by homologous recombination. A floxed stop cassette was
included between promoter and the cDNA allowing Cre-
dependent expression of human Sphk2 gene (Supplementary
Fig. S1). Homozygous human Sphk2 mice with C57BL/6J
background were bred with B6.FVB-Tg(EIIa-Cre)C5379Lmgd/J
mice (no. 003724; The Jackson Lab, Bar Harbor, ME, USA),
carrying a Cre transgene under the control of the adenovirus
EIIa promoter. Breeding with EIIa-Cre mice resulted in a
deletion of the loxP-flanked stop cassette and subsequent
overexpression of human Sphk2. Homozygous tgSphk2 mice,
lacking the stop cassette and the Cre transgene, Sphk2/, and
wild-type controls (C57BL/6J) for all the experiments were
bred from our own colonies.
Oxygen-Induced Retinopathy Model and Retina
Whole-Mount Preparation
Retinal neovascularization was observed using the OIR
model.38,39 Accordingly, neonates together with their mother
were exposed to 75% oxygen from postnatal day (P)7 to P12.
Upon returning to room air (21% O2) at P12 the relative
hypoxia induced NV over the period P12 through P17 in these
mice, with P17 as the maximum of NV. Normoxia controls
were handled in the same environment but without 75% O2
exposure. At P7, P12, P14, and P17, mice were killed, and eyes
were fixed for 1 hour at room temperature in 4% formalde-
hyde. For whole-mount preparation, eyes were placed under a
dissecting microscope and cut open along the ora serrata. After
removing cornea and iris, RPE and sclera were separated from
the retina, following removal of the lens. Isolated retinae were
stained with 100 lL 1 mg/mL TRITC-lectin (BSI) from Griffonia
simplicifolia (Sigma Aldrich, Taufkirchen, Germany) in 1%
Triton X-100, 1 mM CaCl2, 1 mM MgCl2 in 13 PBS overnight,
washed with 13 PBS, and transferred to a microscopic slide.
After four radial incisions, retinae were coverslipped with
mounting medium (DAKO, Hamburg, Germany).39 Whole-
mount retinae were investigated and pictures were taken with
a fluorescence microscope (Keyence BZ-9000; Keyence
Deutschland GmbH, Neu-Isenburg, Germany).
Analysis of Retinal Angiogenesis, Vaso-
Obliteration, and Neovascularization
Vascular density analysis is an important feature to evaluate
retinal angiogenesis. AngioTool40 was used for branching point
quantification at P7, indicating vascular density. The two main
readouts in OIR are vaso-obliteration (VO) and subsequent NV.
VO develops during the hyperoxic phase of the model, and NV
follows from P14 onward. The percentage and therefore extent
of VO were calculated by comparing the central avascular area
to the total retinal area using a photo editing program
(Photoshop; Adobe Corp., San Jose, CA, USA).39 Quantification
of NV was done at P14 and P17 on retina whole mounts using a
computer-aided technique allowing semiautomated quantifica-
tion of retinal NV based on ImageJ software (National Institutes
of Health, Bethesda, MD, USA) together with appropriate plug-
ins and macros.41
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
Retinae from unfixed eyes were used for RNA isolation utilizing
the Masterpure DNA and RNA Isolation Kit (Biozym Scientific
GmbH, Oldendorf, Germany) and the corresponding protocol.
RNA (1 lg) was transcribed into cDNA using a reverse
transcription system (Life Technologies Limited, Paisley, UK).
Quantitative real-time PCR (TaqMan) was performed using the
Applied Biosystems 7500 Fast Real-time PCR System (Darmstadt,
Hessen, Germany). Probes, primers, and the reporter dyes 6-
FAM and VIC were from Life Technologies (Darmstadt,
Germany). Probes used were Mm99999915_g1 (GAPDH),
Mm00445021_m1 (mouse Sphk2), Hs00219999_m1 (human
Sphk2), Mm00456503_m1 (Angpt1), Mm00545822_m1
(Angpt2), Mm00437304_m1 (VEGFa), Mm02619656_s1
(S1PR1), AJVI4VC (S1PR2), Mm02620181_s1 (S1PR3), and
Mm00468695_s1 (S1PR4). Cycling conditions were as follows:
958C for 15 minutes (1 cycle), 958C for 15 seconds, and 608C for
1 minute (40 cycles). Threshold cycle (Ct) was calculated by the
instrument’s software (7500 Fast System SDS Software version
1.4). Analysis of the relative mRNA expression was performed
using the 2DDCt method. The housekeeping gene GAPDH was
used for normalization.
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Sphingolipid Quantification by Liquid
Chromatography Tandem Mass Spectrometry
(LC-MS/MS)
Quantification of sphingolipids was performed by LC-MS/MS.
For quantitation, the retina tissue samples were first mixed
with 150 lL H2O and the internal standards sphingosine-d7,
sphingosine 1-phosphate-d7, and sphinganine-d7 (20 lL of a
solution of 500 ng/mL). The mixture was homogenized using a
swing mill (Retsch, Haan, Germany) with four zirconium oxide
grinding balls for each sample (25 Hz for 2.5 minutes).
Afterward, the samples were extracted twice with 600 lL
methanol:chloroform:HCl (15:83:2, vol/vol/vol). The collected
lower organic phases were evaporated at 458C under a gentle
stream of nitrogen and reconstituted in 50 lL methanol.
Afterward, amounts of sphingolipids were analyzed by liquid
chromatography coupled to tandem mass spectrometry. A
Luna C18 column (150 3 2-mm ID, 5-lm particle size, 100-A˚
pore size; Phenomenex, Aschaffenburg, Germany) was used
for chromatographic separation. The HPLC mobile phases
consisted of water-formic acid (100:0.1, vol/vol) (A) and
acetonitrile-tetrahydrofuran-formic acid (50:50:0.1, vol/vol/
vol) (B). For separation, a gradient program was used at a
flow rate of 0.3 mL/minute. The initial buffer composition 60%
(A)/40% (B) was held for 0.6 minutes and then within 3.9
minutes linearly changed to 0% (A)/100% (B) and held for 6.5
minutes. Subsequently, the composition was linearly changed
within 0.5 minutes to 60% (A)/40% (B) and then held for 4.5
minutes. The running time for every sample (injection volume
of 10 lL) was 16 minutes. The MS/MS analyses were performed
using a triple quadrupole mass spectrometer API4000 (Sciex,
Darmstadt, Germany) equipped with an ESI (electrospray
ionization) ion source operated in positive. The analysis was
done in Multiple Reaction Monitoring (MRM) mode with a
dwell time of 50 ms. Data acquisition was done using Analyst
Software V 1.6 and quantification was performed with Multi-
Quant Software V 3.0 (both Sciex), employing the internal
standard method (isotope dilution mass spectrometry). Linear-
ity of the calibration curve was proven for sphingosine from
0.02 to 5 ng/mg tissue and for S1P from 0.1 to 10 ng/mg tissue;
the coefficient of correlation was at least 0.99. Variations in
accuracy were less than 15% over the whole range of
calibration, except for the lower limit of quantification, where
a variation in accuracy of 20% was accepted.
Statistical Analysis
Analysis was performed using Graph Pad Prism (San Diego, CA,
USA). Statistical tests performed included 1-way analysis of
variance (ANOVA) with Bonferroni’s multiple comparison test
for significance of differences between multiple groups and
Student’s t-test for comparison between two groups. Data are
presented as mean 6 standard deviation (SD). P < 0.05 was
considered statistically significant.
RESULTS
Sphk2/S1P Is Associated With Retinal Vascular
Development
Sphk isoforms are ubiquitously expressed but show differences
in subcellular localizations and tissue-dependent expression
levels.22,25 In the retina of wild-type (WT) mice from P12 to
P17, both kinases are expressed, but expression levels of
Sphk2 were markedly higher (Fig. 1A). Therefore, we focused
on the role of Sphk2, making use of Sphk2/ and tgSphk2
mice (Supplementary Fig. S1). Overexpression of human
Sphk2 in the retina was confirmed by measuring retinal human
Sphk2 mRNA expression (Fig. 1B). This mouse mutant is
characterized by higher retinal S1P levels.
Branching point analysis of TRITC-lectin–stained retinae
from WT, Sphk2/, and tgSphk2 mice on P7 showed a
prematurely dense vessel network in tgSphk2 in comparison to
WT mice, whereas the vessel density was reduced in Sphk2/
mice (Figs. 2A, 2B).
Sphk2 Overexpression Accelerates
Neovascularization in the Hypoxic Phase While
Absence of Sphk2 Leads to Defective Vessel Growth
When subjected to OIR, the central area of VO after 5 days of
hyperoxia (P12) was significantly reduced in tgSphk2 by 14.9%
in comparison to WT mice, whereas Sphk2/ mice showed a
similar avascular area (Fig. 3A, P12). In tgSphk2, coverage of
the avascular area by newly formed vessels occurred faster
than in WT mice, contrary to Sphk2/. At P17, revasculariza-
tion of the avascular area had progressed further in all three
genotypes. In WT mice, the avascular area was reduced by
24.1% from P12 to P17. The initially faster revascularization in
tgSphk2 slowed down, with a total reduction of 20.0%,
FIGURE 1. Sphingosine kinase 2 is the prominent isoform in the retina. (A) Expression of the two isoforms of sphingosine kinase (Sphk1 and Sphk2)
in retina of WT mice 12, 14, and 17 days after birth, measured by qRT-PCR. P, postnatal day; mean 6 SD; n¼5. (B) Expression of human Sphk2 and
mouse Sphk2, measured by qRT-PCR, in tgSphk2 in the retina on all investigated days. Results are mean 6 SD; n¼ 3; *P < 0.05, **P < 0.01.
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resulting in a significantly smaller avascular area at P17. In
Sphk2/ the avascular area decreased by only 17.2% from P12
to P17 (Fig. 2B). To further investigate these differences in the
reduction of the avascular area, the extent of neovasculariza-
tion was evaluated by relating the area covered by NV to the
total retinal area (Fig. 3C) and by observing clusters and tufts of
blood vessels. While tgSphk2 showed significantly increased
NV in comparison to WT mice at all time points, NV was
decreased in Sphk2/. In both strains, the visual appearance of
the blood vessel system clearly differed from WT mice at all
time points. In tgSphk2, clusters and tufts were already formed
at P14, and at the later stage the blood vessel network had a
more chaotic appearance than in WT mice. In Sphk2/ the
blood vessel system appeared even more severely affected than
in the tgSphk2 retina, and a large number of cluster and tufts
were visible (Fig. 3A).
Retinal S1P Levels Are Not Regulated During OIR
Retinal S1P levels did not show significant alterations during
OIR in WT mice. Under normoxia, retinal S1P concentrations
were increased in comparison to WT mice both in tgSphk2
and, counterintuitively, in Sphk2/ mice as has already been
described (and attributed to a compensatory upregulation of
Sphk1) previously for this mutant.42 OIR did not induce further
significant changes of S1P levels (Fig. 4A). Sphingosine, the
precursor of S1P, increased significantly in Sphk2/ but not in
tgSphk2 mice (Fig. 4B).
S1P Receptor Expression Is Differentially
Regulated During the Course of OIR in the
Different Genotypes
In view of the increased retinal S1P levels in tgSphk2 and
Sphk2/ mice, we performed mRNA expression studies on
S1PRs. Retinal S1PR expression was detected for four of the
five receptors (S1PR1 > S1PR3 > S1PR2 > S1PR4, data not
shown). We found a downregulation of S1PR1 at P12 and P14
in OIR in comparison to WT mice of the same age (Fig. 5A).
S1PR2 was upregulated at all time points following OIR; S1PR3
did not show significant changes, and S1PR4 was strongly
upregulated (20-fold) at P12 and P14 and significantly
downregulated at P17 (Figs. 5B–D). S1PR1 showed a lower
baseline expression in tgSphk2 and Sphk2/ mice and OIR did
not induce significant changes (Fig. 5A). The expression of
S1PR2 was also significantly lower in tgSphk2 and Sphk2/,
treatment independent (Fig. 5B). S1PR3 expression was not
regulated differentially in tgSphK2 or Sphk2/ (Fig. 5C).
Strikingly, S1PR4 expression was 10-fold higher in tgSphk2 as
compared to WT mice but did not change significantly upon
OIR. At P17, when NV reaches its maximum, S1PR4 levels
decreased both in WT and tgSphK2 mice subjected to the
FIGURE 2. Sphingosine kinase 2 influences retinal vascularization. (A) Fluorescence TRITC-lectin staining of the vascular structure of P7 whole-
mount retina in WT, tgSphk2, and Sphk2/ mice. Scale bar: 500 lm. (B) Statistical analysis of the number of branching points at P7 in the retina of
WT, tgSphk2, and Sphk2/ mice. Mean 6 SD, n¼ 12, **P < 0.01.
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model. The expression of S1PR4 in Sphk2/ remained very
low (Fig. 5D).
Sphk2 Overexpression Regulates Growth Factor
Expression in a Time-Dependent Manner Whereas
Sphk2/Mice Show a Reduced Capacity to Express
Growth Factors
To elucidate the mechanisms underlying the differential course
of VO and NV in tgSphk2 and Sphk2/, we performed mRNA
expression studies. VEGFa, the initiating factor of neovascular-
ization, was upregulated in OIR from P14 onward in all
genotypes compared to their respective normoxia controls.
Surprisingly, retinae of tgSphk2 mice that underwent acceler-
ated neovascularization in OIR showed lower VEGFa expres-
sion levels than WT mice throughout the whole time course of
the model (Fig. 6A). Compared to WT mice, in Sphk2/ the
VEGFa levels were drastically reduced at all time points under
normoxia as well as in the OIR model, but still showed a slight
increase from P14 onward in OIR (Fig. 6B). Since the
acceleration of neovascularization in tgSphk2 could not be
explained by increasing VEGFa expression upon hypoxia, we
analyzed Angpt1 and Angpt2. In OIR, tgSphk2 mice showed
significantly upregulated Angpt1 and Angpt2 levels in compar-
ison to WT mice at P12, which decreased during the hypoxic
phase (Figs. 7A, 7C). Angpt1 decreased from P14 until it was
down to similarly low levels as observed in WT (Fig. 7A).
Angpt2 expression was downregulated from P12 to P14 but
still higher than in WT. Interestingly, at P17, Angpt2 levels in
WT stayed upregulated, while they were significantly reduced
in tgSphk2 (Fig. 7C). In contrast, Angpt1 in Sphk2/
expression remained low and Angpt2 showed only a moderate
upregulation at P17 (Figs. 7B, 7C).
FIGURE 3. Effect of genetic modulations of Sphk2 on the degree of vasculopathy in the OIR model. (A) WT, tgSphk2, and Sphk2/ retina whole
mounts from postnatal days 12, 14, and 17 were stained with TRITC (tetramethylrhodamine)-conjugated lectin. Scale bar: 500 lm. (B) The central
avascular area is given in % of the total retina area (avascular area bordered by dotted line). (C) NV is given in % of the total retinal area. Results are
means 6 SD; n ¼ 12/group; *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 4. Retinal concentrations of sphingosine 1-phosphate (S1P)
and sphingosine in WT, tgSphk2, and Sphk2/ mice in the OIR model.
Retina levels of S1P (A) and sphingosine (B) were measured by LC-MS/
MS. Results are means 6 SD; n¼8/group; *P < 0.05, **P < 0.01, ***P <
0.001.
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DISCUSSION
The present study investigates the role of Sphk2 in retinal
vascular development and neovascularization. S1P, the catalytic
product of Sphk2, is known to participate in stimulating
angiogenesis and vessel maturation.43 The functional role of S1P
in the retina has been investigated in recent studies, creating
evidence for its important contribution to retinal pathologies,29
retinal and choroidal neovascularization,30 and profibrotic and
proinflammatory responses in pigment epithelium cells.44,45
We demonstrate that genetic modulation of Sphk2 with
corresponding changes of retinal S1P levels leads to a profound
alteration of angiogenesis and accelerated neovascularization
during OIR. In tgSphk2 we observed an accelerated retinal
angiogenesis under physiological conditions and an accelerat-
ed but chaotic neovascularization in OIR when compared to
WT. In contrast, angiogenesis was slowed down in Sphk2/
and neovascularization was severely altered in OIR.
Two recent publications have established S1P signaling via
S1PR1 as a critical but not exclusive signal for inhibition of
angiogenesis and the achievement of vascular stability during
vessel maturation that acts in parallel with Notch signaling but
also independent.27,28 S1PR1-deficient mice displayed a hyper-
sprouting phenotype confirmed and found to be EC specific,
FIGURE 5. S1P receptors expression in tgSphk2 and Sphk2/ retinae in the OIR model. S1P receptor mRNA expression was measured by qRT-PCR
in retinae of WT, tgSphk2, and Sphk2/ mice under normoxia and in the OIR model. Amount of receptor mRNA in retinae was S1PR1 < S1PR3 <
S1PR2 < S1PR4. (A) S1P receptor 1 expression. (B) S1P receptor 2 expression. (C) S1P receptor 3 expression. (D) S1P receptor 4 expression.
Results are means 6 SD; n¼ 6/group; *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 6. Vascular endothelial growth factor alpha (VEGFa) expression is downregulated in tgSphk2 and Sphk2/ retinae in the OIR model.
VEGFa mRNA expression was measured by qRT-PCR in retinae of WT, tgSphk2, and Sphk2/ mice under normoxia and in the OIR model. (A)
Comparison of tgSphk2 with WT mice. (B) Comparison of Sphk2/with WT mice. Results are means 6 SD; n¼6/group; *P < 0.05, **P < 0.01, ***P
< 0.001.
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with S1PR1 expression gradient being low expression in tip
cells of the retinal vasculature.27 In this context, it was shown
that signaling via S1PR1 inhibits VEGF signaling.
The phenotype of our tgSphk2 mice, with lower S1PR1
expression during physiological vessel development until P14,
appears similar to that of S1PR1-deficient mice and showed an
accelerated angiogenesis with neovascular tufts resembling the
angiogenic hypersprouting seen in these mice. In contrast,
Sphk2/ mice showed opposite effects concerning retinal
vascularization, and slightly higher S1PR1 expression at P12
under normoxia compared to tgSphk2. Therefore, differential
expression of the S1PR1 could be a critical determinant of the
neovascularization phenotype of the two mutant strains.
Among the two isoforms of Sphk, we found Sphk2 to be more
prominent in the retina. This has been described in other
neuronal tissues as well.46
We found that the retinal vasculature of tgSphk2 mice is less
sensitive to vessel loss in hyperoxia, which may be due to an
accelerated vessel maturity in comparison to WT at the time
point investigated. However, the neovascularization that
occurs in the hypoxia phase is more chaotic. By contrast,
Sphk2/ mice show a delayed retinal angiogenesis and have a
catastrophic outcome in the OIR model with very sparse and
chaotic neovascularization.
Extracellular S1P regulates a wide range of cellular
processes and physiological functions via its GPCRs, including
the vascular system.32 During the hyperoxia phase of OIR, a
significant downregulation of S1PR1 and an upregulation of
S1PR2 occur. Generally, S1PR1 protects vascular integrity in
many pathologic states, whereas S1PR2 is presumed to mediate
vascular damage and endothelial barrier dysfunction.33 Con-
cerning the role of S1PR1 as an angiogenic stop signal that has
been recently discovered, a rapid downregulation of S1PR1
starting at P12, when the mice are transferred from hyperoxia
to room air and neovascularization sets in to compensate for
the vessel loss, may be one mechanism to unleash vessel
regrowth in the avascular area. The most strikingly regulated
S1P receptor, however, was S1PR4. This is a novel and
somewhat unexpected finding as S1PR4 has been hitherto
known as an S1PR on lymphoid cells involved in the regulation
of immune responses. However, our group has found a
significant expression on brain endothelial cells (data not
shown) and we propose that S1PR4 acts in concert with S1PR1
(and S1PR2) and, in the case of tgSphk2 mice, might be
massively upregulated to compensate for the downregulation
of S1PR1. Overall, the changes we observed in S1PR1 and -2 in
relation to S1PR4 expression suggest a potential compensatory
response by S1PR4. But also, S1PR1-independent functions of
S1PR4 in angiogenesis should be further investigated. Our data
FIGURE 7. Angiopoietin 1 and 2 expression in tgSphk2 and Sphk2/ mice. Angiopoietin 1 (Angpt1) and angiopoietin 2 (Angpt2) mRNA expression
was measured by qRT-PCR in retinae of WT, tgSphk2, and Sphk2/ mice under normoxia and in the OIR model. (A) Angpt1 levels in tgSphk2 and
WT mice. (B) Angpt1 expression in Sphk2/ and WT mice. (C) Angpt2 levels in tgSphk2 and WT mice. (D) Angpt2 expression in Sphk2/ and WT
mice. Results are means 6 SD; n ¼ 6/group; *P < 0.05, **P < 0.01, ***P < 0.001.
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indicate a possible functional role and an interplay of S1P
receptors in OIR in the retina that is modulated by
overexpression of Sphk2. To the best of our knowledge, there
are no reports on a direct regulation of S1PR expression by
either Sphk1 or Sphk2.
Since the level of oxygen is the main driver of the
pathophysiological processes in OIR, we investigated the
hypoxia-driven signaling molecules VEGFa and Angpt1 and -2
in the context of Sphk2 modulation. VEGFa acting via VEGF
receptor 2 (VEGFR2) lays a critical role in retinal angiogenesis
and neovascularization. It acts in concert with the Tie2
pathway. Tie2/Angpt1 activation leads to vessel stabilization
and maturation,9 whereas Angpt2 contributes to developmen-
tal vessel sprouting and vessel destabilization,10,11 and both are
needed for new blood vessel formation.10 In contrast, Angpt1
suppresses retinal and choroidal neovascularization.4
Interestingly, our tgSphk2 mice despite their phenotype did
not show significant differences in VEGFa levels. However, at
P12 following the hyperoxia phase, they showed higher levels
of Angpt2 and also a higher expression of the stabilizing
Angpt1, working hand in hand with VEGFa to mediate
angiogenesis, leading to enhanced angiogenesis, maturation,
and reduced vessel loss. Under hypoxia, tgSphk2 mice showed
a similar drop in Angpt1 as WT mice, but an accelerated time
course of Angpt2 expression with an early upregulation in
presence of VEGFa to induce neovascularization and a faster
return to baseline levels, which may explain the observed
excess of neovascularization.
Sphk2/ mice showed a dramatic deficiency in VEGFa,
Angpt1, and Angpt2 expression both under normoxia and
under OIR. The downregulation of Angpt1 and Angpt2 leads to
a delayed retinal vascularization. Hypoxia hardly triggered an
increase of VEGFa, Angpt1, and Angpt2 expression in this
genotype. Only the expression of Angpt2 increased at the later
time point of the hypoxia phase, but this is inefficient since in
the context of low VEGFa levels, Angpt2 has been shown to
promote regression of neovascularization.12 This may explain
the severely defective vessel regrowth in Sphk2/.
Interaction between S1P signaling pathway and vascular
growth factors has already been described. S1P has been
shown to transactivate the VEGFR, even in the absence of
VEGFa,47 indicating S1P and VEGFa acting in concert
concerning certain signaling functions, and may explain some
of the (sparse) retinal neovascularization seen in OIR in
Sphk2/. On the other hand, S1PR1 signaling has been shown
to inhibit intracellular effects of VEGFa transduced by VEGFR2,
a mechanism assumed to underlie the limitation of angiogenic
sprouting by S1PR1.28 The apparent discrepancy of the
reported findings may result from the pleiotropic actions of
S1P and the potentially opposing downstream effects of the
different S1PRs. Even though the modulation of retinal S1P
concentrations as measured by LC-MS/MS appears to be only
moderate, local paracrine receptor-mediated and intracellular
signaling processes that are not reflected in tissue S1P level
could be active. We found a strong interplay between Sphk2
and S1PR expression associated with an impressive alteration
of the disease course in OIR. Our data suggest that increase
Sphk2 activity and loss of S1PR1 lead to accelerated
neovascularization. Concerning S1P-directed therapy, so far
mainly an S1P neutralizing antibody (sonepcizumab) has been
tried in animal studies, and first clinical trials in humans yielded
contradictory results (positive in mice, neutral in humans).
Therefore, stage-specific pharmacologic inhibition of Sphk2
and S1P receptors may offer therapeutic potential to treat
retinal diseases involving neovascularization, for example,
diabetic retinopathy, retinopathy of prematurity, and retinal
vein occlusion.
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